Compare DexCom, Inc. (DXCM) vs InMode Ltd (INMD) Price & Performance

DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.

The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.

INMD trades at $15.36, up 2.92% today, with a bullish technical signal from moving averages. The company maintains strong profitability with a 77.84% gross margin and 23.27% net margin, while valuation ratios appear attractive with a P/E of 11.32. Recent news includes an unsolicited acquisition offer of $16.75 per share from Steel Partners and Q2 2026 revenue guidance of $95.2M-$95.4M.

The stock presents a mixed outlook: upside exists from potential acquisition interest and solid fundamentals, but risks include a recent earnings miss, ongoing securities fraud investigations, and overbought technical indicators. Analyst consensus is divided with a $16.50 price target suggesting moderate upside from current levels.